Wednesday, October 4, 2023
Wednesday, October 4, 2023

Contact: 561.316.3330

KA Imaging To Launch Premium Dual-Energy Mobile System at AHRA

X-ray manufacturer KA Imaging is unveiling its Reveal Mobi Pro dual-energy mobile X-ray system. The product, which is a collaboration with UMG/Del Medical, will be showcased at the upcoming AHRA Annual Meeting.

“This partnership with Del Medical comes at an excellent time,” said Amol Karnick, President and CEO of KA Imaging. “After the pandemic, mobile imaging has become more prominent in many healthcare facilities, so offering a solution to improve the visualization of bones and tissues at the bedside is essential,” said Karnick.

“We are excited to support KA Imaging and their enhanced detector technology for the conventional and mobile radiographic markets,” said Marc Lorenzo, Executive Vice President at Del Medical.

The Reveal Mobi Pro integrates KA Imaging’s Reveal™ 35C detector with SpectralDR™ technology into a complete mobile X-ray solution. Reveal’s ability to simultaneously acquire conventional and dual-energy images with a single exposure at the bedside improves hospital and patient outcomes and protects revenue by reducing outflows.

The Reveal 35C detector mimics the workflow, dose and techniques of state-of-the-art mobile DR X-ray. With the Reveal Mobi Pro, it is offered in a fully integrated mobile system.

Last November, KA Imaging unveiled its first integrated mobile dual-energy X-ray system, Reveal Mobi Lite. The main difference between the Lite and Pro versions are around some advanced features, only available in the Pro system. The most noteworthy feature of the Reveal Mobi Pro is the telescopic arm. In addition to the collapsible column design, the system has a high-frequency 40KW generator, integrated DR Workstation, 8-hour battery life, and motor-assisted movement.

The AHRA Annual Meeting will be held from July 9-12 at Indiana Convention Center. KA Imaging has booth #329.

The Reveal 35C detector is FDA 510(k) cleared. The Reveal Mobi Pro is coming soon and is not available for sale.

Busy year

Earlier this year, the company announced Robert (Bob) Thompson as an executive advisor, bringing 30 plus years of experience in medical devices. Before joining the company, Thompson was the President for Siemens Healthineers Ultrasound. He also held several leadership positions at GE Healthcare.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Ariceum Therapeutics’ Targeted Radiopharmaceutical 177Lu-satoreotide Exhibits Promising Clinical Response and Good Tolerability Profile in Patients with Advanced Neuroendocrine Tumours

Satoreotide combines Ariceum’s proprietary peptide satoreotide - a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SSTR2) - with the radioactive isotope ‘payload’ 177Lutetium. SSTR2 is a cell surface protein often overexpressed in certain cancers, including NETs and small cell lung cancer (SCLC).

New Hot Start Isothermal Mixes Boost Sensitivity, Specificity, and Speed of DNA Target Detection

Isothermal mixes are important in a range of isothermal amplification applications, including whole genome amplification, point-of-care assay development and testing, and strand displacement amplification for synthetic biology. However, a common issue with isothermal mixes is non-specific amplification — where primers bind to unintended DNA targets — because amplification often takes place at a fixed temperature which may favour non-specific primer interactions, contrary to PCR. Isothermal mixes can also lead to primer dimer formation, where primers associate with each other and are extended by the polymerase.

Branded Legacy Invests Heavily in Innovation and Growth with $540,000 Expansion

This strategic initiative underscores Branded Legacy's unwavering commitment to innovation, quality, and customer satisfaction. The expansion project is set to infuse over $500,000 worth of inventory into the company, reinforcing its position as a leader in the market.

Cue Biopharma Completes Patient Enrollment in Ph1b Head & Neck Cancer Trial

“Completing the enrollment of the recommended phase 2 dose patient expansion cohort is an important milestone as the data from this trial guides further development plans and associated discussions with the Food and Drug Administration (FDA),” said Daniel Passeri, chief executive officer of Cue Biopharma.

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Michelle Fraser, head of cell and gene therapy at Revvity, underscores the importance of providing broad access to this technology: "Base editing has been extensively demonstrated in numerous studies to safely and precisely control the correction of single base changes at multiple target sites, simultaneously. This streamlined approach simplifies complex multi-gene editing, holding great promise for the development of new cell therapies targeting rare inherited genetic diseases, cancer, and in the creation of universal donor cells as the foundation of allogeneic cell therapies."

By using this website you agree to accept Medical Device News Magazine Privacy Policy